- Conditions
- Cystic Fibrosis
- Interventions
- Placebo Respimat, Tiotropium bromide 5 mcg, tiotropium bromide-low dose-2.5mcg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Not listed
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • San Diego, California • Jacksonville, Florida + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 673
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Diseases, Healthy
- Interventions
- Zongertinib (BI 1810631)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- HIV Infections
- Interventions
- Protease inhibitor tipranavir
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 40 more
- Conditions
- Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Survodutide, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more
- Conditions
- Neuroendocrine Neoplasms
- Interventions
- BI 764532, Carboplatin, Etoposide, Cisplatin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more
- Conditions
- Venous Thromboembolism, Secondary Prevention
- Interventions
- dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 9
- States / cities
- Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
- Conditions
- HIV Infections, Peripheral Nervous System Disease
- Interventions
- Mexiletine hydrochloride, Benztropine mesylate, Amitriptyline hydrochloride
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1997
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 34
- States / cities
- Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more
- Conditions
- Psoriasis
- Interventions
- BI 655066 (very high i.v. dose), Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Burbank, California • Miami, Florida • Port Orange, Florida + 4 more
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo, Survodutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 81 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Downey, California • Los Angeles, California + 11 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Educational Intervention
- Other
- Lead sponsor
- Humana Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 4,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Afatinib, pembrolizumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- HIV Infections
- Interventions
- NO BI Drug administered
- Behavioral
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 18 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 34
- States / cities
- Bakersfield, California • Beverly Hills, California • Fountain Valley, California + 27 more
- Conditions
- Urological Manifestations
- Interventions
- tamsulosin hydrochloride
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Hoover, Alabama + 35 more
- Conditions
- Constipation
- Interventions
- Not listed
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 5 Years to 8 Years
- Enrollment
- 1,430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 11
- States / cities
- Madison, Wisconsin • Stoughton, Wisconsin
- Conditions
- Colitis, Ulcerative
- Interventions
- Spesolimab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more
- Conditions
- HIV Infections
- Interventions
- Nevirapine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Months to 13 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Head and Neck Cancer, Squamous Cell Cancer
- Interventions
- Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Basking Ridge, New Jersey • New York, New York
- Conditions
- Lung Cancer, Lung Metastases
- Interventions
- Nintedanib, Prednisone, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 12
- States / cities
- Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62,197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Stiolto Respimat, Placebo Respimat
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BI 1744, bi1744, Placebo, Foradil
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 11
- States / cities
- Tampa, Florida • Overland Park, Kansas • Lafayette, Louisiana + 7 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BEA 2180 BR, tiotropium
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 84 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 13
- States / cities
- Lakewood, California • Wheat Ridge, Colorado • Pembroke Farms, Florida + 10 more